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Summary Objective comparison of different antipsoriatic therapies requires quantitative assessment of disease
severity. However, clinical assessment with the widely used Psoriasis Area and Severity Index (PASI)
inaccuracy. An alternative is the quantitative analysis of different epidermal cell
parameters using multiparameter flow cytometry. Our aim in the present study was to compare 
the clinical and flow cytometric approach to monitor disease activity and to evaluate antipsoriatic 
efficacy. Clinical scores for erythema, induration and scaling were assessed and biopsies for flow 
cytometric analysis were obtained from the psoriatic plaques of 89 patients before and after
treatment with different therapeutic regimens consisting of vitamin D3 analogues and cortico­
steroids. In total, 219 epidermal cell suspensions were analysed using triple-labelling, with the 
simultaneous staining of markers for epidermal proliferation (DNA dye TO-PRO-3), differentiation 
(antikeratin 10), and inflammation (antivimentin).
Correlation analysis was performed on 166 paired values obtained from 83 patients. A highly 
significant correlation was observed between erythema and the percentage of vimentin-positive cells, 
between scaling and the percentage of keratin 10 positive keratinocytes, and between induration and 
the number of basal keratinocytes in the S- and G2M phase, when all 166 biopsies were assessed. The 
correlation remained in the same range if the analysis was restricted to the 83 pretreatment biopsies. 
In contrast to the clinical scores, the flow cytometric analysis permitted a clear separation between 
the antiproliferative and anti-inflammatory or keratinization-enhancing effects of antipsoriatic
The
combination of calcipotriol and a topical corticosteroid improved all cell biological markers
treatment. The vitamin D ? analogues proved to exert a mainly
substantially, and clobetasol monotherapy had a powerful effect on these markers. In conclusion, 
multiparameter flow cytometry has been shown to be a sensitive tool to evaluate the growth inhi­
biting, anti-inflammatory and keratinization-enhancing effects of antipsoriatic therapies.
In the evaluation of antipsoriatic therapies, quantitative 
assessment of disease severity is essential. A popular and 
frequently used method for clinical assessment is the 
Psoriasis Area and Severity Index (PASI). In this scoring 
system, described by Fredriksson and Pettersson,1
percentage involvement and degree of erythema, indu-
and desquamation is estimated in four body 
areas. Using a formula, an ordinal value between 0 
and 72 can be calculated. However, the authors stated 
that the PASI score should not to be regarded as an 
‘exact’ numerical value, as the severity rating is sub­
jective. Marks et a l 2 demonstrated a wide interobserver 
error of even well-designed clinical assessment tech­
niques, especially with respect to the calculation of the 
involved areas. Various groups have emphasized the
potential for inaccurate conclusions when
I  A.clinical assessment alone is used. Therefore, there is 
clearly a need for objective measurements of psoriasis
Flow cytometry permits quantitative analysis of dif­
ferent cell parameters and can be applied to epidermal 
single-cell suspensions prepared from normal and dis­
eased skin.s In analogy to the clinical signs which reflect 
the pathological changes in psoriasis, we developed a 
triple-labelling procedure with simultaneous staining of 
markers for epidermal proliferation (DNA content), dif­
ferentiation (antikeratin 10), and inflammation (anti-
with the development of a 
dermo-epidermal separation method using thermolysin, 
it has become possible to perform this flow cytometric
a.
on cell sus 
8
s prepi from 3 mm
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In the present study we have analysed 219 epidermal 
single cell suspensions prepared from keratotome and 
punch biopsies of psoriatic plaques from 89 patients 
before and after treatment with different therapy regi­
mens consisting of vitamin D3 analogues and topical 
corticosteroids. Our aim in the study was to compare 
the clinical and How cytometric approaches in moni­
toring disease activity and to establish whether flow 
cytometry is a valuable tool to evaluate and compare 
antipsoriatic therapies. We addressed in particular: to 
what extent the clinical scores for erythema, induration
and desquamation correlate with percentage of
vimentin-positive cells, the percentage of basal kera- 
tinocytes in the S- and G2M phase and the percentage of 
keratin 10 positive keratinocytes; to what extent the 
improvement of clinical parameters reflects a change in 
the cell biological markers: whether the method of prep­
aration of cell suspensions influences the association of 
clinical and flow cytometric scores; and whether clinical 
and flow cytometric scores vary with different antipsori­
atic therapies.
Materials and methods
Patients, treatment regimens and biopsy procedures
Data from 89 patients in total with psoriatic plaques 
were analysed. Patients’ details have been described in
our How cytometric studies on the treatment of psoriatic 
plaques with l a ,24 dihydroxyvitamin Dj ointment 
(Tacalcitol®), 4 |xg/g applied once daily for 8 weeks or 
placebo/ calcipotriol, 50 |xg/g once daily, twice daily or 
in combination with the topical corticosteroids clobeta- 
sone 17-butyrate, ()-5mg/g, and betamethasone 17- 
valerate, 1 mg/g, for 8 weeks,9 and after treatment with 
clobetasol 1 7-propionate (unpublished data), 
wash-out period of 2 weeks, representative psoriatic
raa, 
i were 
treat-
3d. Clinical scores for ei:
l < desquamation of
, on a scale, before and
mem. Scoring was performed by one investigator only, 
to avoid the interobserver error by Marks el
al.2 Skin samples of the selected test were obtained 
simultaneously with clinical scoring. In this way 2.19 
single-cell suspensions, derived from 152 keratotome 
biopsies and 67 punch biopsies, were prepared for flow 
cytometric analysis.
Single-cell suspensions and staining 
Epidermal cell suspensions from keratotome
were prepared using a trypsin separation method. The 
cell isolation procedure on punch biopsies consisted of 
dermo-epidermal separation with thermolysin and sub­
sequent incubation with trypsin. In flow cytometric 
studies of epidermis, the quality of cell suspensions is 
essential. As enzymatic and mechanical methods are 
used to separate the cells, membrane antigens are easily 
damaged. Therefore, we decided to use a multipara­
meter technique with simultaneous quantification of 
the DNA content and of the intermediate filaments. 
These filaments are resistant to breakdown and anti-
are well-studied. Several keratins are 
expressed in the epidermis. Keratin 10 is a well-known 
epidermal differentiation marker. Vimentin is expressed 
in all epidermal mesenchymal cells, i.e. dendritic cells 
and (especially in psoriatic skin) inflammatory infiltrate
cells. A detailed of both cell isolation
methods and the staining procedure for multiparameter 
flow cytometric analysis have been published.8
isolation, cells were fixed in 70% w/v ethanol until 
required for staining.
Multiparameter flow cytometry by the simultaneous 
measurement of fluorescein-isothiocyanate (FITC), phyco- 
erythrin (PE) and propidiumiodide (PI) is considered 
difficult because of the large spectral overlap of PE and 
PI. Hoechst 33342 and 7AAD have been proposed as 
alternatives to PI in multiparameter flow cytometry. 
However, in our hands, 7AAD gave unacceptably high 
coefficients of variation (CVs). Hoechst 3 3 342 staining 
requires an expensive ultraviolet laser, which is usually 
not present in commercial flow cytometers. On the con­
trary, many research flow cytometers are equipped with 
a low-power HeNe laser (6 3 3 nm), which excites TO- 
PRO-3 iodide (TP 3) (peak absorbance at 642 nm). The 
quality of staining with TP 3 has been extensively studied 
by our group.6 At a concentration of 1 |xmol/L, typical 
cell cycle histograms of peripheral blood lymphocytes
showed a CVof 3*6%. The detei 
mouse cell lines S-phase fracti 
showed a good correlation. C
of human i 
TP 5 and PI 
with FITC and
PE, TP 3 was superior to PI as a DNA stain in 
parameter flow cytometry.
Spectral overlap of the lluoroehromes pr
vcbe minimal. After a first incubation for 30 min 
vimentin (Vim3B4, mouse IgG2a, Novocastra Labora­
tories Ltd, Newcastle upon Tyne, U.K.) and antikeratin 
10 (RKSE60, mouse IgGl, Department of Molecular 
Biology, University of Maastricht, The Netherlands), a 
second incubation for 15 min with the lluoroehromes 
FITC and PE conjugated to monoclonal goat antibodies
mouse IgG2a i
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Associates, Birmingham, AL, U.S.A.), 
respectively, was performed. After a third washing step, 
DNA staining was performed by addition of 300 jxL TP 3 
(I |xmol/L in phosphate-buffered saline (PBS)) (Molecu­
lar Probes, Eugene, OR, U.S.A.) and 50 jxL RNase 
(1 mg/mL in PBS) (Sigma, St Louis, MO, U.S.A.).
The flow cytometric analysis of triple-stained cell sus­
pensions has been described before.7,8 From each sample, 
5000-10,000 gated cells were measured and analysed
using an EPICS Elite flow cytometer (Coulter, Luton, 
U.K.) equipped with a dual laser system. PE and FITC 
were excited with an air-cooled argon ion laser (15 mW, 
488 nm). TP3 was excited with a HeNe laser (10 mW, 
633iim). Fluorescence was measured using bandpass 
filters of 5 2 0 -5 3 0 nm (green, FITC), 5 5 5 -5 9 5 nm 
(orange, PE), and 6 7 0 -6 8 0  nm (red, TP3). The area/ 
peak ratio of the red signal (DNA) was used to discri­
minate between doublets of diploid cells (clumps) and
1 f \
real single tetraploid cells. After setting appropriate 
gates with the EPICS® Elite software, the percentages 
of vimentin-positive cells, differentiated keratinocytes 
(vimentin negative and keratin 10 positive) and basal 
keratinocytes (vimentin negative and keratin 10 nega-
were calculated. Using Multicycle1M software 
(Phoenix Flow Systems, San Diego, CA, U.S.A.) the 
percentages of basal keratinocytes in the S- and G2M 
phases of the cell cycle (proliferation) were calculated 
from DNA histograms.
Analysis of the correlation between clinical and flow 
cytometric scores was performed by calculation of the 
Pearson correlation coefficient. In the placebo-con­
trolled l a ,24 dihydroxyvitamin D* study four biopsies 
were obtained per m corticosteroid
monotherapy study three biopsies were obtained per 
patient. Therefore, to avoid within-person variability, 
correlation analysis was restricted to paired values, i.e. 
before and after treatment, with omission of the values 
of the placebo-treated lesions. This resulted in 166 paired 
values obtained from 83 patients. To compare the flow 
cytometric scores before treatment for both cell isolation 
procedures, the paired ¿-test for means (two-tail) was 
used.
Results
In all the 219
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Figure 1. Correlation of clinical scores and How cytometric values 
(mean ±  SKM) of 166  lest lesions, (a) The erythema score vs. the 
percentage of vimentin-positive cells; (b) the desquamation score vs. 
the percentage of keratin 10 positive keratinocytes: and U'l the 
induration score vs. the percentage of basal keratinocytes in the S- 
and CJjiM phase, The number of biopsies is indicated above the error 
bars.
number of intact cells was at least 30% (without debris 
and 
were <
s). Coefficients of variation of the Gi pe<
. In Figure 1 we show the results of the
cor re it a n t of clinical and flow cytometric
to 166 paired values of 
83 patients. It can be seen that high clinical scores for
© 1997 British Association of Dermatologists, British Journal ofDcr II, 137, 3 6 7 -3 7 5
370  C.P.GLADE et al.
Table I. Correlation coefficients oi' clinical and How 
lesions before treatment (it =  83)
ic scores (relative percentage of cells) of all psoriatic lesions (n =  166) and psoriatic
% Vimentin- 
positive P
% Keratin 
.10-positive P
% basal 
cells in S- or 
GjM-phase P Erythema P Induration P
n =  166
% Vimentin 1
% Keratin 10 - 0 - 3 8 < 00001 1
% S- or (LM phase 0-37 < 0 -0 0 0 1 - 0 - 1 3 0-087 1
Erythema 0-41 < 0 -0 0 0 1 - 0 - 3 2 < 0-00 01 0-62 < 0 -0 0 0 1 1
Induration 0-44 < 0 -0 0 0 1 —0-40 < 0-00 01 0-66 < 0 -0 0 0 1 0*84 < 0 -0 0 0 1 1
Desquamation 0-3 7 < 0-0001 —0-44 < 0 -0 0 0 1 0-61 < 0 -0 0 0 1 0*79 < 0 -0 0 0 1 0-87  < 0 -0 0 0 1
II 00 LtJ
% Vimentin 1
% Keratin 10 — 0'19 0 -086 1
% S- or GjM-phase 0 -084 0-45 0-25 0-021 1
Erythema 0-22 0 -044 0-16 0-14 0-44 < 0 -0 0 0 1 1
induration 0-35 0 -0 0 1 0 -0 * 0 1 2 0-91 0-52 < 0 -0 0 0 1 0-54 < 0 -0 0 0 1 1
Desquamation 0-093 0-40 -0 * 1 9 0-080 0-32 < 0 -0 0 3 6 0-23 0 -0 3 6 0-52  < 0 -0 0 0 1
erythema correlate with high percentages of vimentin-
positive cells (Fig. la; correlation coefficient r 0-41,
P< 0*0001 ), that the desquamation score inversely 
correlates with the number of keratin 10 positive
keratinocytes (Fig. lb; r= -0 * 4 4 , P< 0*0001) and that
the induration of a psoriatic plaque correlates with its 
proliferative activity (Fig. 1c; r=0*66, P<0*0001). 
High correlation coefficients were shown between the 
clinical scores of the psoriatic plaques: 0*79 (erythema 
and desquamation), 0 8 4  (erythema and induration), and 
0*87 (induration and desquamation) with P <0*0001 
(Table 1). However, the coefficients of the flow cyto­
metric values were — 0*38, P<0*0001 (vimentin and 
keratin 10); 0*37, P<0*0001 (vimentin and SG2M); 
and —0-13 (not significant) (SG2M and keratin 10).
To exclude a possible effect of the treatment regimen 
on the degree of corrélation, analysis of coefficients was 
also performed on values from biopsies obtained before 
treatment (n =  83). Table 1 shows that the correlation 
coefficients of clinical scores of untreated lesions only 
were reduced to 0*23 (P<0*05, erythema and desqua­
mation), 0*54 (P < 0*0001, erythema and induration), 
and 0*52 (P < 0*0001, induration and desquamation), 
whereas the correlations between the flow cytometric 
values remained below the level of statistical signifi­
cance or strongly changed. Furthermore, it can be seen 
from Table 1 that, compared with the assessment on all 
lesions, the correlation in untreated lesions between 
basal cells in S- or G2M phase, and induration, remained 
in the same range (r =  0*52; P < 0*0001). The associ­
ation between erythema/vimentin and desquamation/
keratin 10 was reduced to the lower values of 0*22 
(P<0'05) and —0*19 (not significant), respectively. To 
find out whether a change in clinical scores was 
reflected in changes in the flow cytometric scores, 
correlation analysis was performed on the differences 
of these scores before and after treatment. Figure 2 
clearly shows that some degree of correlation exists. 
Quantitative analysis revealed correlation coefficients of
1 0-14 (not significant, Fig. 2a), 1 0*28 (P<0-01,
Fig. 2b) and r =  0*19 (P = (H )8 , Fig. 2c).
In the present study, epidermal single-cell suspensions 
were prepared according to two different methods. Cell 
isolation of dermatotome biopsies (area 1 cm2 thickness 
0*4 mm) was obtained after a one-step trypsin incuba­
tion method. Three millimetre punch biopsies were 
processed using a two-step thermolysin-trypsin separa­
tion method. The question was addressed as to whether 
the cell isolation procedures influence the flow cyto­
metric results. Therefore, in Table 2, the mean pretreat­
ment flow cytometric values of each clinical score are 
given for both methods of cell isolation. It can be seen 
that all corresponding flow 
(except for psoriatic plaques with an induration score 
of 1 and very scaly lesions) were significantly lower in 
epidermal cell suspensions prepared from punch biop­
sies, compared with dermatotome biopsies.
The results of the flow cytometric analysis, comparing 
both absolute and relative changes after different anti- 
psoriatic therapy regimens and after placebo therapy, 
are given in Figure 3. With respect to epidermal prolif­
erative activity (Fig. 3a, percentage basal keratinocytes
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Figure 2. Correlation of differences before and after treatment of 
clinical and How cytometric parameters (mean ±  SEM) of 83 test 
lesions, (a) The erythema score vs. the percentage of vimentin-positive 
cells; (b) the desquamation score vs. the percentage of keratin 10 
positive keratinocyles; and (c) the induration score vs. the percentage
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in the S and G2M phase), 8 weeks of placebo treatment 
resulted in a reduction of 15% compared with the pre­
treatment situation. Both calcipotriol cream (50fxg/g, 
applied twice daily) and l a , 24 dihydroxyvitamin D3 oint­
ment (4 |xg/g, applied once daily) resulted in a reduc­
tion in proliferative activity of 34%. The application of 
calcipotriol cream (50 jxg/g once daily), however, resulted
of How
absolute (mean ±  SEM) c 
¿trie parameters after different i
the percentage of keratin 10 positive keratinocytes (c). DV, calcipotriol 
once daily and vehicle once daily; TAC, Tacalcitol® ( l a ,24 dihydroxy­
vitamin Dj) ointment once daily; DD, calcipotriol twice daily; DC, 
calcipotriol once daily and clobetasone butyrate once daily; DB, 
calcipotriol once daily and betamethasone valerate once daily; C,
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Clinical score Flow cytometric score Dermatotome Punch A (%) P
Hrythema 1 Vimentin (%) 1 7-4 6 ‘4 63 < 0-001
3 14-2 7-1 50 <0*01
Induration 1 S- or GiM-phase (%) 9-8 10-3 —5*1 NS
14-2 9-3 55 <0*01
3 19-6 12-4 35 < 0 0 5
Desquamation 1 Keratin !()(% ) 50-3 29-8 41 < 0 0 5
4 5 4 32-1 29 < 0 0 5
3 35-2 2 6 ’6 2 4 < 0 0 5
4 36-8 26-6 28 NS
Table 2. Comparison of pretreatment How 
cytometric values (relative percentage of 
cells) of punch and dermatotome biopsies 
prepared by different cell isolation procedures 
(h=  102). A implies the difference of values 
obtained by punch biopsies and dermatotome 
biopsies as a percentage of the value in 
dermatotome biopsies.
[Dermatotome] — [Punch] n#wwlJ
A =  -------- — ------------------ :---------X 100%
[Dermatotome]
in a reduction of only 23%. The combination of topical 
corticosteroids and calcipotriol further increased the 
effect on epidermal proliferation. The reduction of pro­
liferative activity in psoriatic plaques, treated for a 
maximum of 3 weeks with clobetasol 17-propionate, 
proved to be 76%. With respect to the number of 
vimentin-positive cells (Fig. 3b), placebo treatment and 
monotherapy with the vitamin D3 analogues resulted 
in reductions of less than 23%. This is in contrast to 
treatment regimens comprising corticosteroids (combi­
nation or monotherapy), where reductions of 31-65% 
were observed. In Figure 3c, we indicate the effect of 
different antipsoriatic therapies on the number of kera­
tin 10 positive keratinocytes (differentiation marker). 
Monotherapy with the vitamin Dj analogues l a ,24 
dihydroxy vitamin D* and calcipotriol (once daily or
Discussion
e daily) resulted in an increase of 15-23%. A 
combination of calcipotriol and topical steroids did not 
seem to increase this percentage substantially. In con­
trast, the monotherapy of psoriatic plaques with clobe­
tasol 17-propionate increased the number of keratin 10
keratinocytes by 87%, compared with an 
increase of 36% for placebo.
In Figure 4 we summarized the effect of the different 
antipsoriatic therapies on the clinical scores of the test 
lesions. Therapy regimens using topical corticosteroids 
proved to have a more pronounced effect on erythema
compared with monotherapy with vitamin D 5 ana­
logues. The effect of placebo on the reduction of the 
erythema score was only 15% (Fig. 4a). All therapies 
showed a substantial reduction (50% or more) with 
respect to the induration score, in contrast to placebo 
(28%, Fig. 4b). The mean desquamation score was 
reduced by 42% after treatment with placebo, which 
implies that this parameter is placebo-sensitive. Mono 
or combination therapy using vitamin D3 analogues 
showed reductions in desquamation values of 58-81% 
(Fig. 4c).
A highly significant correlation was observed between 
erythema and the percentage of vimentin-positive cells, 
between scaling and the percentage of keratin 10 posi­
tive cells, and between induration and the percentage of 
basal cells in the S- and G2M phase, if all 166 biopsies 
are considered. The latter correlation remained equally 
pronounced, whereas the other two associations were 
less prominent, if the analysis was restricted to 8 3 biop­
sies taken from untreated skin.
The percentage of vimentin-positive cells consists, to a 
large extent, of inflammatory cells. Although erythema, 
i.e. vasodilatation, is part of cutaneous inflammation, 
the appearance of inflammatory cells in the epidermis 
might have a different course. In the marginal zone of 
spreading psoriatic plaques, significant changes in the 
microvasculature are visible well before the appearance
of an inflammatory infiltrate. 1 1,1.2 rTherefore, the incom-
plete correlation between the percentage of vimentin- 
positive cells in the epidermis and erythema can be 
explained by the partly independent changes of the 
microvasculature and the appearance of an infiltrate 
in the epidermis. Induration of the psoriatic plaque is 
supposed to be related to epidermal proliferation. 
Indeed, the high correlation between the percentage 
basal cells in the S- and G2M phase, and the induration 
score, is in line with this commonly held belief. As the 
formation of scale in the psoriatic plaque represents 
impaired differentiation, the distribution between the 
number of basal (keratin 10 negative) and suprabasal 
(keratin 10 positive) keratinocytes was presumed to be 
indicative of the desquamation score. However, because 
of the reduction of keratin 10 at some sites in the
psoriatic lesion, this differentiation marker does not
1 iseem to visualize all suprabasal cells. We also should 
reconcile the observation that keratin 10 is not a 
marker which includes all aspects of differentiation.
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Figure 4. Comparison of the absolute (mean ±  SUM) and relative (%) 
changes of clinical scores after different antipsoriatic treatments with 
respect to erythema (a), induration (b), and desquamation (c). 1)V, 
calcipotriol once daily and vehicle once daily; TAC, Tacalcitol® ( l a , 24  
dihydroxyvitamin D }) ointment once daily; DD, calcipotriol twice 
daily; DC, calcipotriol once daily and elobetasone butyrate once 
daily; D13, calcipotriol once daily and betamethasone valerate once 
daily; C, clobetasol 1 7-propionate.
Therefore, the correlation between scaling and keratin 
10 expression has to be an incomplete one.
A description of the improvement in psoriatic plaques 
can be made clinically. The PASI score has been popular 
and practical, and adequate for comparative analysis. 
However, the interobserver variability is large.2 It has 
been suggested by van de Kerkhof4 that the scores of 
erythema, induration and scaling should be considered 
separately, as these markers provide information on the 
anti-inflammatory vs. the antiproliferative capacity of 
treatment. The present study, however, suggests that the 
three scores are, to a large extent, correlated, which 
implies that the sum of these scores might be a more 
appropriate reflection of the psoriatic process. Such a 
sum might be the combined result of the cell biological 
denominator of the three processes. But we have to 
consider the possibility that this correlation, at least to 
some extent, is introduced by the unblinded investigator 
who, biased by a severe erythema, scaling or induration, 
might overinterpret the remaining signs. An important 
aspect of flow cytometric assessment during experimen­
tal treatment of psoriasis is the discrimination between 
antiproliferative, keratinization-enhancing and anti­
inflammatory effects in vivo. As demonstrated by corre­
lation studies, the clinical parameters do not adequately 
permit this separation.
Vimentin can be used as a marker for epidermal 
infiltrate, showing higher values in psoriatic compared 
with normal skin. In Table 2 , we compared pretreat­
ment flow cytometric values of both separation methods 
in psoriatic skin, with equal erythema scores. As the 
epidermal infiltrate is assumed to be equal, and inter­
ference by treatment is excluded, the difference in the 
numbers of vimentin-positive cells may be accounted for 
by dermal infiltration. The data in Table 2 show that 
biopsy and preparation procedure has a clear impact on 
flow cytometric values reached. The objective for
derma-epidermal separation method, 
on punch biopsies, was to obtain 
high-quality cell suspensions with low al con lain
ination and a high yield of basal cells. Indeed, for each 
erythema score, the number of vimentin
in cell suspensions prepared from 
punch biopsies compared with dermatotome biopsies, 
indicating low dermal contamination. The suprabasal 
compartment (keratin 10 positive) is significantly smal­
ler in cell suspensions prepared from punch 
indicating the presence of a larger quantity of basal 
cells. It seems likely that a 0*4 mm derrm 
does not always contain all epidermal cells. Furthermore, 
in contrast to thermolysin, enzymatic separation with
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trypsin sometimes cleaves above the dermo-epidermal 
junction, resulting in a loss of basal cells. A lower pro­
liferative activity in the basal compartment was found 
in the cell suspensions prepared from punch biopsies. 
This might be the result of less clumping in the cell 
suspension, as clumps mimic cells with a tetraploid DNA 
content. Another explanation for the lower percentage 
of basal cells in the S- and G2M phase might be the yield 
of a larger quantity of non-proliferating or slowly pro­
liferating stem cells, which have been suggested to be 
located at the tips of the rete ridges.
Although a comparison of different studies is hazar­
dous due to preselection bias and subjective factors in 
clinical scoring, we have summarized the flow cyto­
metric and clinical assessments of the efficacy of several 
topical antipsoriatic treatments in Figures 3 and 4. As 
different preparation methods were used, it is important 
to consider relative improvement only and to refrain 
from a comparison of absolute values. The placebo (the 
application of a bland emollient) had a substantial effect 
on the percentage of keratin 10 positive keratinocytes (a 
36% increase in average counts). This effect on cell 
biology is in line with the tendency of the placebo to 
improve desquamation (by 42%), whereas induration 
and erythema are improved by 28% and 16%, respec­
tively. Previously, we have demonstrated a reduction in 
the suprabasal expression of involucrin and the resto­
ration of filaggrin expression during treatment with a 
hydrocolloid.16 In the present study, we again suggest 
that improvement in the suprabasal compartment 
results from the artificial restoration of the skin barrier 
by an ointment.
The flow cytometric quantification reveals a compar­
able effect of calcipotriol, once or twice daily, with 
respect to the percentage of keratin 10 positive kera­
tinocytes and the percentage of vimentin-positive cells. 
However, the reduction of basal cells in the S- and G->M 
phase was comparable for la ,  2 4 dihydroxy vitamin D
ointment (Tacalcitol®) once daily and calcipotriol twice 
daily, whereas once daily calcipotriol had a smaller effect 
on this proliferation marker. A comparison of clinical 
markers suggests that calcipotriol once and twice daily, 
and l a , 24 dihydroxyvitamin Dj ointment once daily, 
induce an improvement well above that seen with 
placebo, with l a ,24 dihydroxyvitamin D3 ointment tend­
ing to be slightly less effective. The twice daily applica­
tion of calcipotriol resulted in a greater improvement in 
scaling. Monotherapy with vitamin D3 analogues had a 
small effect on the percentage of vimentin-positive cells 
and the percentage of keratin 10 positive keratinocytes, 
at a level comparable with placebo. Interestingly, the
addition of a topical corticosteroid to calcipotriol sub­
stantially enhanced the reduction of the percentage of 
vimentin-positive cells and, to a lesser extent, compen­
sated for the abnormally low number of keratin 10 posi­
tive keratinocytes. Therefore, flow cytometric analysis 
suggests a powerful antipsoriatic effect for combination 
treatment of calcipotriol and a topical corticosteroid. 
This is, to some extent, expressed at the clinical level by 
the erythema score (see Fig. 4a). Clinical practice, how­
ever, has shown that the combination of calcipotriol and 
a topical corticosteroid has a major effect on recalcitrant 
psoriatic plaques. Treatment with a potent cortico­
steroid, such as clobetasol 17-propionate, is the most 
powerful topical antipsoriatic treatment available. Its 
effect 011 the percentage of basal keratinocytes in the S- 
and G2M phase, the percentage of vimentin-positive 
cells and the percentage of keratin 10 positive kerati­
nocytes, is enormous. This effect is clearly seen clinically.
In conclusion, the clinical severity scores of psoriatic 
plaques are correlated to such an extent that they do not 
permit a separation between the effects on hyperproli­
feration, inflammation and differentiation by antipsori­
atic treatment. Triple-labelling flow cytometry permits 
the demonstration of antipsoriatic effects beyond the 
clinical scores, as assessed by the investigator, and further 
permits differentiation between the anti-inflammatory, 
growth inhibiting and keratinization-enhancing capa­
city of antipsoriatic treatments.
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